<DOC>
	<DOCNO>NCT02617732</DOCNO>
	<brief_summary>The purpose study evaluate effect safety Tianqi Capsule glucose variability patient type 2 diabetes continuous blood glucose monitoring system .</brief_summary>
	<brief_title>Effects Tianqi Capsule Glucose Variability Patients With Type 2 Diabetes .</brief_title>
	<detailed_description>Diabetes become threat human health independent risk factor macrovascular microvascular disease . Large prospective clinical study show strong relationship time-averaged mean level glycemia measure HbA1c diabetes complication . However , recent year several piece evidence indicate glucose variability may also contribute development diabetes complication . Thus , glucose variability may become new target treatment diabetes . Traditional Chinese medicine，a kind multitargeted compound , may contribute maintain blood glucose homeostasis diabetes . Tianqi capsule ( Chinese herb extract ) Chinese patent medicine approve treat T2DM China . Previous clinical study show Tianqi capsule could lower blood glucose measure HbA1c . What 's , Tianqi capsule also prove improve glycometabolism lipid metabolism T2DM IGT . This research adopt randomize , open , parallel double blind , placebo control clinical method . The patient , meet eligibility criterion , divide experimental group placebo group treat 12 week . A main outcome，glucose variability detect continuous blood glucose monitoring system could obtain continuous comprehensive blood glucose `` glucose sensor '' . The influence Tianqi capsule glucose variability type 2 diabetes evaluate .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion Criteria 18.5kg/m2≤BMI≤35.0 kg/m2 ; meet type 2 diabetes mellitus diagnostic criterion publish 1999 WHO ; blood variability , define standard deviation blood glucose 3.5mmol／L within 2 day selfmonitoring blood glucose（SMBG） ( 5 time per day ) diabetic duration 1 year ; stable condition 4 week unchanged lifestyle drug intervention ; （permit take metformin sulphonylureas dosage unchanged study period ） HbA1c≤10％ ; sign informed consent form . acute diabetes complication （e.g . diabetic ketoacidosis，diabetic hyperosmolar coma , diabetic lactic acidosis , Hypoglycemic coma） severe chronic diabetes complication ( e.g . diabetic retinopathy stage 4~6 , severe diabetic nephropathy need dialysis on） gastrointestinal disease serious influence digestive function disorder absorption endocrine disease ( hyperthyroidism , acromegaly , Cushing 's syndrome . ) severe heart disease ( acute myocardium infarction , unstable angina , heart failure NYHA functional classification III IV） moderate severe liver function abnormality ( ALT , TBil AST &gt; double upper limit ) moderate severe renal function abnormality ( eGFR &lt; 50ml／min ) blood leukocyte &lt; 4.0×10^9/L ; blood thrombocyte＜90×10^9/L take drug affect glucose metabolism , glucocorticoid serious illness consider exacerbate lifethreaten fellow period ; evidence mental disorder ; alcoholic drug abuse female pregnant , lactating , planning pregnancy , sexually active contraceptive measure ; participate clinical trial within 3 month ; condition researcher think unable evaluate curative effect finish study . allergic ingredient herbs contain Tianqi capsule</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>glucose variability</keyword>
	<keyword>continuous glucose mornitoring system</keyword>
	<keyword>traditional Chinese medicine</keyword>
</DOC>